secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001082554-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY
-----------------------------------------------------------------------

- Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.
- Full-year net income $1.195B ($24.64 diluted EPS) vs $984.8M in 2023 (diluted EPS $19.81).
- Tyvaso franchise revenue grew 31% to $1.62B in 2024, driven by Tyvaso DPI (up 41%).
- Completed $1B accelerated share repurchase, repurchasing ~3.55M shares.
- Recorded $71.1M litigation accrual for Sandoz; R&D expense up 18% on organ projects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/0001082554-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/uthr-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001082554-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer